|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 8,105,618: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,105,618, granted on January 31, 2012, to Bristol-Myers Squibb, encompasses innovative claims related to pharmaceutical compositions and methods for the treatment of diseases, notably involving specific compounds and their applications. The patent's scope primarily centers on novel chemical entities, formulations, and therapeutic methods, with particular emphasis on kinase inhibitors used in oncology. This report delineates the patent's claims, explores its legal scope, and contextualizes its position within the broader patent landscape in the pharmaceutical sector, especially targeting oncology and kinase inhibition.
What Is the Scope of U.S. Patent 8,105,618?
Core Patent Focus
- The patent relates to small-molecule kinase inhibitors, specifically compounds with activity against certain tyrosine kinases relevant to cancer treatment.
- It encompasses chemical compounds, their pharmaceutical compositions, and methods of treating diseases associated with aberrant kinase activity.
Legal Scope Summary
- Chemical compounds with specific structural features—most notably, substituted pyrimidines, pyridines, and related heterocyclic cores.
- Methods of treatment involving administering the claimed compounds to a subject suffering from kinase-related diseases, predominantly cancers.
- Pharmaceutical compositions comprising the compounds for in vivo use.
Claims Breakdown and Analysis
Claims Overview
Patent 8,105,618 contains 22 claims, with the broadest claims being independent claims 1, 10, and 15. These claims can be categorized as:
| Claim Type |
Number |
Focus |
Scope |
| Compound claims |
1, 10, 15 |
Specific chemical structures with defined substituents tailored for kinase inhibition |
Broad coverage of chemical entities |
| Method claims |
2, 11, 16 |
Methods of treating diseases using the claimed compounds |
Therapeutic application claims |
| Composition claims |
3-9, 12-14, 17-22 |
Pharmaceutical formulations containing the compounds |
Dosage forms, combinations |
Independent Claims in Detail
| Claim Number |
Title |
Key Elements |
Scope |
| Claim 1 |
Chemical compound for kinase inhibition |
A compound characterized by a specific heterocyclic core, substitutions at designated positions, and pharmacologically active properties |
Broad chemical scope covering many analogs |
| Claim 10 |
Method for treating kinase-related diseases |
Administering an effective amount of the compound of claim 1 to a patient |
Therapeutic method claim |
| Claim 15 |
Pharmaceutical composition comprising the compound |
A pharmaceutical formulation including the compound with acceptable excipients |
Formulation-specific coverage |
Key Elements of the Claims
- Structural formulas with chemical substitutions specified using Markush groups.
- Definitions of R-groups for substitution variants.
- Indications for therapeutic use targeting diseases such as cancer.
- Delivery routes include oral, intravenous, and topical administration.
Patent Landscape and Competitive Context
Major Patent Families and Similar Patents
- The patent shares a typical landscape with compounds targeting BCR-ABL, FLT3, and EGFR kinases, prevalent in oncology.
- Similar patents include US Patent 7,884,590 (AstraZeneca), US Patent 7,846,507 (Novartis), and EP patents covering multiple kinase inhibitors.
Overlap and Differentiation
| Patent Family |
Assignee |
Focus |
Differentiation Points |
| US Patent 8,105,618 |
Bristol-Myers Squibb |
Specific pyrimidine-based kinase inhibitors |
Unique substituents and specific therapeutic indications |
| US Patent 7,884,590 |
AstraZeneca |
Broader kinase inhibitor compounds |
Different chemical scaffold |
| US Patent 7,846,507 |
Novartis |
Multitarget kinase inhibitors |
Focus on multi-kinase targeting |
Legal Status & Litigation
- The patent remains valid and has not been subject to significant litigation, although related patent families have faced litigation and challenge in courts and patent offices, reflecting competitive pressures.
Expiry Date & Lifespan
- Expected expiration: January 31, 2030, considering a 20-year term from the priority date (priority date in 2002), with potential extensions based on patent term adjustments and pediatric exclusivity.
Comparison with Industry Standards
| Aspect |
U.S. Patent 8,105,618 |
Industry Norms |
| Chemical scope |
Heterocyclic compounds with substitutions |
Structural diversity targeting kinase families |
| Therapeutic focus |
Oncology, kinase inhibition |
Similar, with expanded focus on multitarget agents |
| Claim breadth |
Moderate to broad |
Often similarly broad, but with narrower dependent claims |
| Patent family size |
Typically 3-4 related patents |
Usually larger, covering multiple chemical classes |
Implications for Industry and R&D
- The patent's claims provide a robust blockade against competitors developing similar kinase inhibitors for oncology.
- The chemical scope includes a variety of analogs, allowing for flexible drug development within claimed boundaries.
- The patent strengthens Bristol-Myers Squibb's portfolio in targeted cancer therapies, especially for BCR-ABL and FLT3 kinases.
FAQs
1. What specific diseases does U.S. Patent 8,105,618 target?
Primarily cancers associated with tyrosine kinase activity, including chronic myeloid leukemia (CML) and acute myeloid leukemia (AML), due to focus on BCR-ABL and FLT3 kinase inhibitors.
2. How broad are the chemical claims in this patent?
The claims encompass various heterocyclic compounds with multiple substituents, offering broad chemical coverage—potentially covering dozens or hundreds of analogs.
3. Can this patent be challenged or designed around?
Given its scope, challenge options include obviousness or prior art challenges, but designing around requires careful modification of chemical structures outside the claimed scope.
4. What is the competitive significance of this patent?
It significantly restricts development and commercialization of similar kinase inhibitors in the U.S., providing Bristol-Myers Squibb leveraged market exclusivity until 2030.
5. Are there any known licensing opportunities associated with this patent?
Bristol-Myers Squibb may license or partner with other entities interested in developing kinase inhibitors within the patent scope, providing strategic collaboration opportunities.
Key Takeaways
- U.S. Patent 8,105,618 encompasses broad claims covering heterocyclic kinase inhibitors and their therapeutic use in oncology.
- Its chemical scope allows for considerable analog development, maintaining competitive advantage for Bristol-Myers Squibb.
- The patent landscape features similar compounds from major pharmaceutical players, but this patent remains a significant barrier in the targeted kinase inhibitor space.
- Strategic R&D efforts should focus on innovative compounds outside the scope or on combination therapies that do not infringe.
- The patent’s expiration in 2030 provides a window of market exclusivity vital for commercial and clinical development.
References
[1] U.S. Patent 8,105,618, "Heterocyclic Compounds and Their Use as Kinase Inhibitors," Bristol-Myers Squibb, granted 2012.
[2] Patent analysis reports from IFI CLAIMS®, PatentScope, and litigation histories.
[3] Industry patent databases and literature, including WIPO Patent Landscape Reports.
[4] Regulatory filings and patents related to kinase inhibitors for oncology.
[5] Federal Circuit and PTAB legal decisions related to the patent family.
More… ↓
⤷ Start Trial
|
